Hao Ru-Tian, Zhang Xiao-Hua, Pan Yi-Fei, Liu Hai-Guang, Xiang You-Qun, Wan Li, Wu Xiu-Ling
Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, China.
J Cancer Res Clin Oncol. 2010 Sep;136(9):1349-57. doi: 10.1007/s00432-010-0786-y. Epub 2010 Feb 6.
The aim of this study was to investigate the expression of the PRL-3 in human invasive breast cancer and to evaluate its clinical and prognostic significance. Its potential role in the invasive-metastatic properties of invasive breast cancer was also investigated.
Protein expression of PRL-3 was evaluated by immunohistochemistry for a consecutive series of 82 invasive human breast cancer tissues and 63 matched lymph node metastases, including PRL-3 mRNA expression analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) in malignant, nonmalignant breast tissue samples and lymph node metastases. We investigated the correlation of PRL-3 with clinicopathologic features, Overall and recurrence-free survival distribution curves were assessed using the Kaplan-Meier test and log-rank statistics, followed by Cox proportional hazards regression model.
We found that 70.7% patients expressed a high level of PRL-3 protein in their tumors, and its over expression was positive correlated with lymph node metastasis (LNM) (P = 0.011). Moreover, The PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue, while increased expression of PRL-3 mRNA was significantly associated with LNM (P = 0.002). Univariate analysis showed that the positive expression of PRL-3 was a poor risk prognostic factor (OS, P = 0.045; RFS, P = 0.034). Multivariate analysis using the Cox regression model indicated that high PRL-3 expression was an independent unfavorable prognostic factor for RFS.
These results strongly suggest that PRL-3 expression can indicate the potential role of LNM to some extent. Increasing the risk of tumor metastasis (OR = 3.889). Our results also imply that PRL-3 might be a novel molecular marker for predicting relapse of invasive breast cancer.
本研究旨在调查PRL-3在人浸润性乳腺癌中的表达,并评估其临床和预后意义。还研究了其在浸润性乳腺癌侵袭转移特性中的潜在作用。
采用免疫组织化学法对连续的82例人浸润性乳腺癌组织和63例匹配的淋巴结转移灶进行PRL-3蛋白表达评估,包括通过逆转录聚合酶链反应(RT-PCR)分析恶性、非恶性乳腺组织样本和淋巴结转移灶中的PRL-3 mRNA表达。我们研究了PRL-3与临床病理特征的相关性,使用Kaplan-Meier检验和对数秩统计评估总生存和无复发生存分布曲线,随后进行Cox比例风险回归模型分析。
我们发现70.7%的患者肿瘤中PRL-3蛋白表达水平较高,其过度表达与淋巴结转移(LNM)呈正相关(P = 0.011)。此外,与良性乳腺组织相比,恶性乳腺组织中PRL-3 mRNA表达显著更高,而PRL-3 mRNA表达增加与LNM显著相关(P = 0.002)。单因素分析显示PRL-3的阳性表达是一个不良风险预后因素(总生存,P = 0.045;无复发生存,P = 0.034)。使用Cox回归模型的多因素分析表明,高PRL-3表达是无复发生存的独立不良预后因素。
这些结果强烈表明PRL-3表达在一定程度上可指示淋巴结转移的潜在作用。增加肿瘤转移风险(OR = 3.889)。我们的结果还暗示PRL-3可能是预测浸润性乳腺癌复发的一种新型分子标志物。